Nasally reaching brain
and spinal cord

Nasally reaching brain
and spinal cord

Nasal drug delivery platform MetP

  • fully developed and proven effective and safe
  • providing partners with new possibilities for product development
  • created by enthusiasts

Enabling easy delivering of drugs

Nasal drug delivery provides more than therapy of colds or allergies: It enables the administration of systemic-acting drugs with low oral bioavailability and of drugs that are difficult to deliver via routes other than injection.

Furthermore, nasal drug delivery is an excellent – and often ideal – option in the treatment of neurological diseases, including the delivery of biologics with restricted access to the Central Nervous System.

Example 1: Uptake of tritiated testosterone

A pre-clinical study using the MetP technology for targeting the brain:


Compelling: The uptake of tritiated testosterone by the brain was about twice as high after intranasal administration as after intravenous administration.

Banks et al.: «About two-thirds of the testosterone entering the brain after i.n. [intranasal] administration did so by direct entry by nasal routes and the remainder indirectly by first entering the blood and then crossing the blood-brain barrier.»

Banks WA et al.; Delivery of testosterone to the brain by intranasal administration: comparison to intravenous testosterone; J Drug Target. 2009 Feb;17(2):91-7

Example 2: Amygdala activity

A clinical study using the MetP technology for targeting the human brain:


Consider the amygdala reactivity after a single nasal administration of testosterone.

  1. Significant amygdala activity in the placebo condition of young women.
  2. No significant amygdala activity in the placebo condition of middle-aged women.
  3. Significant amygdala activity in middle-aged women after a single nasal administration of testosterone MetP.

Van Wingen et al.: «The middle-aged women received a single nasal dose of testosterone in a double-blind, placebo-controlled, crossover manner, which rapidly increased amygdala reactivity to a level comparable to the young women.»


van Wingen GA et al.;Testosterone increases amygdala reactivity in middle-aged women to a young adulthood level; Neuropsychopharmacology. 2009 Feb;34(3):539-47

Constraints on a nasal drug delivery system

The development of a suitable nasal drug delivery system is challenging, due to:

  • the anatomical and biological factors of the nasal cavity,
  • the physicochemical properties of the drugs,
  • the properties of the formulation,
  • and the availability of a suitable application device to ensure that the drug is delivered to the target site in the nasal cavity.

Therefore, nose-to-brain delivery requires a perfect synergy of active ingredient, carrier formulation and nasal applicator.

This is, where MetP’s drug delivery platform fits in – it is fully developed, proven effective and safe, and furthermore it is extensively patent-protected.

The MetP’s nasal drug delivery system

Our MetP’s platform consists of a breakthrough formulation, an absolutely easy to use application device – and the possibility to serve mass market:

Silcum, our MetP's semi-solid gel matrix, is safe and versatile. Its formulation is perfectly adjusted to the anatomical and biological factors of the nasal cavity as well as easily adaptable to the physicochemical properties of a wide range of drugs: Silcum provides a slow elimination of drugs by mucociliary clearance and a tunable release of the drug.

Lecticula, our MetP’s single-dose nasal applicator, is, of course, properly tailored to the anatomical characteristics of the nose, yet flawlessly easy to handle, and even more: This mono-dose application device is 100 percent sterile and it delivers the exact dosage of the drug, completely independent from head position.

Maxima, our efficient filling technology, allows to serve mass market and to produce pilot samples.

Our MetP’s platform for nasal drug application is proven effective and suitable for a wide range of substances, providing overwhelming benefits, both clinical and competitive – perhaps also for your substance or molecule.

Viral infection

August 24, 2020 — New nasal gel evaluated for its protective action against human rhinovirus 16 (HRV-A16) infection in nasal epithelial cells

Air pollution

August 4, 2020 — MetP Pharma receives US patent for its medical device product “Nasal Pharmaceutical Compositions For Reducing The Risks Of Exposure To Air Pollutants”, Term of patent 2038

Multiple sclerosis

December 9, 2019 — MetP Pharma receives US patent for drug therapy of demyelinating and neuroinflammatory diseases such as multiple sclerosis

Air pollution-induced inflammation

October 4, 2018 — MetP Pharma introduces Nascum-Plus against the onset of air pollution-induced inflammation

Ask your questions, we’re looking forward to hearing from you.

At MetP, we use our unique nasal drug delivery platform for inhouse product development, and we have already succesfully introduced products into the market.

Claudia Mattern, CSO
Udo Mattern, CEO
Phone +41-41-618 30 30
Email

Summary

Nasal applications are possible for a wide range of substances, providing overwhelming benefits. Our proven and patented single-dose nasal applicator Lecticula delivers drugs easily and safely to the systemic circulation and the brain respectively, 100 percent sterile, dosage fully accurate. Our semi-solid formulation Silcum is easily adaptable to a wide range of drugs. Our filling technology Maxima allows to produce pilot samples and to serve mass market. Our own nasally applied drug and OTC products are perfectly well accepted. MetP Pharma AG is a private company and based near Lucerne, Switzerland, held by us, Claudia Mattern, PhD, CSO, and Udo Mattern, CEO.

Udo Mattern CEO and Chairman MetP Pharma AG

«What is your molecule? Have it delivered nasally, using our safe formulation and easy to use mono-dose device.»

Udo Mattern CEO and Chairman MetP Pharma AG